Robert S. Busch

4.5k total citations · 3 hit papers
45 papers, 1.3k citations indexed

About

Robert S. Busch is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Robert S. Busch has authored 45 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Surgery and 13 papers in Molecular Biology. Recurrent topics in Robert S. Busch's work include Diabetes Management and Research (24 papers), Diabetes Treatment and Management (23 papers) and Metabolism, Diabetes, and Cancer (11 papers). Robert S. Busch is often cited by papers focused on Diabetes Management and Research (24 papers), Diabetes Treatment and Management (23 papers) and Metabolism, Diabetes, and Cancer (11 papers). Robert S. Busch collaborates with scholars based in United States, Denmark and Canada. Robert S. Busch's co-authors include Michael P. Kane, Katherine R. Tuttle, Alan G. Zimmermann, Fady T. Botros, Brian Rayner, Mark Lakshmanan, Robert A. Hamilton, Athena Philis‐Tsimikas, Gary Bakst and Bernhard Ludvik and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and Diabetes.

In The Last Decade

Robert S. Busch

42 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

2018 460 citations Katherine R. Tuttle, Mark Lakshmanan et al. The Lancet Diabetes & Endocrinology profile →
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

2019 267 citations Bernard Zinman, Vaishali Bhosekar et al. The Lancet Diabetes & Endocrinology profile →
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

2024 74 citations Johannes F.E. Mann, Peter Rossing et al. Nature Medicine profile →

Peers

Countries citing papers authored by Robert S. Busch

Since Specialization

Citations

This map shows the geographic impact of Robert S. Busch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert S. Busch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert S. Busch more than expected).

Fields of papers citing papers by Robert S. Busch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert S. Busch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert S. Busch. The network helps show where Robert S. Busch may publish in the future.

Co-authorship network of co-authors of Robert S. Busch

This figure shows the co-authorship network connecting the top 25 collaborators of Robert S. Busch. A scholar is included among the top collaborators of Robert S. Busch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert S. Busch. Robert S. Busch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The role of blood testing in prevention, diagnosis, and management of chronic diseases: A review 2024 ·The American Journal of the Medical Sciences ·(unknown), Thu H. Le, (unknown), (unknown), (unknown), (unknown), Robert S. Busch	11
2	Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone 2024 ·BMJ Open ·Ralph A. DeFronzo, Richard J. Auchus, Irina Bancos, Lawrence Blonde, Robert S. Busch, John B. Buse, James W. Findling, Vivian Fonseca, Juan P. Frías, Oksana Hamidi, Yehuda Handelsman, Richard E. Pratley, Julio Rosenstock, Iulia Cristina Tudor, Andreas Moraitis, Daniel Einhorn	0
3	Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial breakdown → 2024 ·Nature Medicine ·Johannes F.E. Mann, Peter Rossing, George L. Bakris, (unknown), Heidrun Bosch‐Traberg, Robert S. Busch, David M. Charytan, Samy Hadjadj, Pieter Gillard, José Luis Górriz, Thomas Idorn, Linong Ji, Kenneth W. Mahaffey, Vlado Perkovic, Søren Rasmussen, Roland E. Schmieder, Richard E. Pratley, Katherine R. Tuttle	74
4	Best-Practice Perspectives on Improving Early Detection and Management of Chronic Kidney Disease Associated With Type 2 Diabetes in Primary Care 2024 ·Clinical Diabetes ·Jennifer D. Goldman, Robert S. Busch, Eden Miller	2
5	Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists 2021 ·Journal of Cardiovascular Pharmacology and Therapeutics ·Dhiren Patel, Robert S. Busch	4
6	The Occurrence and Burden of Hypophosphatasia in an Ambulatory Care Endocrinology Practice 2021 ·Endocrine Practice ·(unknown), Robert S. Busch, Michael P. Kane	3
7	Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial breakdown → 2019 ·The Lancet Diabetes & Endocrinology ·Bernard Zinman, Vaishali Bhosekar, Robert S. Busch, Ingrid Holst, Bernhard Ludvik, Desirée Thielke, James Thrasher, Vincent Woo, Athena Philis‐Tsimikas	267
8	Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial breakdown → 2018 ·The Lancet Diabetes & Endocrinology ·Katherine R. Tuttle, Mark Lakshmanan, Brian Rayner, Robert S. Busch, Alan G. Zimmermann, (unknown), Fady T. Botros	460
9	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 ·Drugs in R&D ·David J. Webb, Blai Coll, Hiddo J.L. Heerspink, Dennis L. Andress, Yili Pritchett, John J. Brennan, Mark T. Houser, Ricardo Correa‐Rotter, Donald E. Kohan, Hirofumi Makino, Vlado Perkovic, Giuseppe Remuzzi, Sheldon W. Tobe, Robert Toto, Robert S. Busch, Pablo E. Pérgola, Hans‐Henrik Parving, Dick de Zeeuw	7
10	Colesevelam Hydrochloride-Ezetimibe Combination Lipid-Lowering Therapy in Patients with Diabetes or Metabolic Syndrome and a History of Statin Intolerance 2007 ·Endocrine Practice ·(unknown), Michael P. Kane, Robert S. Busch, Gary Bakst, Robert A. Hamilton	44
11	Glucose-Monitoring with Continuous Subcutaneous Microdialysis in Neonatal Diabetes Mellitus 2006 ·Klinische Pädiatrie ·F. A. M. Baumeister, (unknown), Robert S. Busch	6
12	Precision and accuracy of two blood glucose meters: FreeStyle Flash versus One Touch Ultra 2006 ·American Journal of Health-System Pharmacy ·(unknown), Michael P. Kane, Gary Bakst, Robert S. Busch, Robert A. Hamilton	19
13	The Utility of Oral Diabetes Medications in Type 2 Diabetes of the Young 2005 ·Current Diabetes Reviews ·Michael P. Kane, (unknown), Robert S. Busch	39
14	The Utility of Insulin Glargine in the Treatment of Diabetes Mellitus 2004 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Jeffrey S. Stroup, Michael P. Kane, Robert S. Busch, Gary Bakst, Robert A. Hamilton	4
15	Substitution of Pioglitazone for Troglitazone in Patients with Type 2 Diabetes 2004 ·Endocrine Practice ·Michael P. Kane, Robert S. Busch, Gary Bakst, Robert A. Hamilton	3
16	The Diabetes Home Visitation Program 2003 ·American Journal of Pharmaceutical Education ·Jeffrey S. Stroup, Michael P. Kane, Robert S. Busch, Gary Bakst, Robert A. Hamilton	1
17	Accuracy of home blood glucose monitors using forearm blood samples: FreeStyle versus One Touch Ultra 2003 ·American Journal of Health-System Pharmacy ·(unknown), Michael P. Kane, Gary Bakst, Robert S. Busch, Robert A. Hamilton	17
18	Cholesterol and Glycemic Effects of Niaspan in Patients with Type 2 Diabetes 2001 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Michael P. Kane, Robert A. Hamilton, (unknown), Robert S. Busch, Gary Bakst	13
19	Rapid onset of severe retinopathy, cataracts and neuropathy in young patients with diabetes mellitus 1992 ·Acta Paediatrica ·Patricia B. Carroll, Raymonde D Herskowitz, Andrew Goodman, Robert S. Busch, Richard S. Beaser	7
20	Effects of Prolactin and Growth Hormone on Tissue and Serum Carnitine in the Rat* 1988 ·Endocrinology ·Andrew Goodman, (unknown), Robert S. Busch, Gregg S. Meyer, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact